Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascletis and 3-V Bio Start US-China Trial of NASH Candidate

publication date: May 1, 2019

Ascletis of Hangzhou and San Francisco's 3-V Biosciences have started a US-China Phase II clinical trial of their partnered treatment for non-alcoholic steatohepatitis (NASH). Ascletis acquired China rights to TVB-2640/ASC40, a fatty acid synthase (FASN) inhibitor, earlier this year when it led a $18 Series E financing in 3-V Biosciences. The trial will evaluate the candidate in about 90 US NASH and 25-30 China NASH patients. Ascletis focuses on liver diseases with several approved treatments for hepatitis C. More details....

Stock Symbol: (HK: 1672)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.